| Nov 1 |
Teva long-acting olanzapine shows improvements in schizophrenia patients
|
| Nov 1 |
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
|
| Nov 1 |
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well ...
|
| Nov 1 |
Countdown to Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
|
| Nov 1 |
EC fines Teva $502m over multiple sclerosis treatment Copaxone practices
|
| Oct 31 |
Teva fined $500M by EU for disparaging rival MS drug (update)
|
| Oct 31 |
EU Commission fines Teva $500 million for trying to stop rival's multiple sclerosis drug
|
| Oct 31 |
Teva Fined Around $500 Million by EU Over MS Drug Competition Concerns
|
| Oct 31 |
Teva Statement on European Commission Decision; Company to Appeal
|
| Oct 26 |
Investors in Teva Pharmaceutical Industries (NYSE:TEVA) have seen impressive returns of 120% over the past year
|
